CD274 and neoplasm: Given the enrichment of PD-L1 in MPNSTs and the ability of MSU-42011 to modulate the immune landscape, combining MSU-42011 with immune checkpoint inhibitors such as anti-PD-1 or anti-PD-L1 may further enhance anti-tumor immunity.